Telomerase Gene Amplification as a Prognostic Marker in Lung Cancer
Author Information
Author(s): Zhu C-Q, Cutz J-C, Liu N, Lau D, Shepherd F A, Squire J A, Tsao M-S
Primary Institution: Ontario Cancer Institute, University Health Network, Toronto, Canada
Hypothesis
The study evaluates the prognostic value of hTERT gene amplification and mRNA overexpression in non-small-cell lung cancer (NSCLC).
Conclusion
hTERT gene amplification is an independent poor prognostic marker for disease-free survival in NSCLC.
Supporting Evidence
- 57% of primary NSCLC specimens demonstrated hTERT amplification.
- Adenocarcinoma showed higher rates of hTERT amplification compared to squamous cell carcinoma.
- Overexpression of hTERT mRNA was noted in 74% of tumours.
- Patients with hTERT amplification had poorer recurrence-free survival.
Takeaway
This study found that a specific gene related to telomerase, which helps cancer cells grow, is often amplified in lung cancer and can predict how well patients will do after treatment.
Methodology
The study used quantitative polymerase chain reaction (qPCR) and fluorescence in situ hybridization (FISH) to assess hTERT gene copy number and mRNA expression in lung cancer specimens.
Limitations
The study had a high frequency of patients lost to follow-up after 3 years, which may affect survival estimates.
Participant Demographics
More than 90% of patients were stage I–II, with a mean age of 69 years.
Statistical Information
P-Value
P=0.03
Confidence Interval
95% CI 1.07–4.37
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website